Immunotoxins (Immunotoxin)

Subscribe to Selected New Research on Immunotoxins

1153 relevant articles (147 outcomes, 163 trials/studies) found for this Bio-Agent

Description: Semisynthetic conjugates of various toxic molecules, including RADIOACTIVE ISOTOPES and bacterial or plant TOXINS, with specific immune substances such as IMMUNOGLOBULINS; MONOCLONAL ANTIBODIES; and ANTIGENS. The antitumor or antiviral immune substance carries the toxin to the tumor or infected cell where the toxin exerts its poisonous effect.

Also Known As:

Immunotoxin; Affinotoxins; Chimeric Toxin; Monoclonal Antibody-Toxin Conjugates; Toxin Carrier; Toxin Conjugate; Antibody Toxin Conjugates; Antibody Toxin Hybrids; Antibody-Toxin Conjugates, Monoclonal; Carrier, Toxin; Carriers, Toxin; Conjugate, Toxin; Conjugates, Antibody-Toxin; Conjugates, Cytotoxin-Antibody; Conjugates, Monoclonal Antibody-Toxin; Conjugates, Toxin; Conjugates, Toxin-Antibody; Cytotoxin Antibody Conjugates; Hybrids, Antibody-Toxin; Hybrids, Toxin-Antibody; Monoclonal Antibody Toxin Conjugates; Toxin Antibody Conjugates; Toxin Antibody Hybrids; Toxin, Chimeric; Antibody-Toxin Conjugates; Antibody-Toxin Hybrids; Chimeric Toxins; Cytotoxin-Antibody Conjugates; Targeted Toxins; Toxin Carriers; Toxin Conjugates; Toxin-Antibody Conjugates; Toxin-Antibody Hybrids; Toxins, Chimeric; Toxins, Targeted

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Pastan, Ira: 23 articles (01/2008 - 02/2002)
2.	Kreitman, Robert J: 14 articles (10/2007 - 02/2002)
3.	Hassan, Raffit: 11 articles (12/2007 - 11/2002)
4.	Vitetta, E S: 9 articles (11/2006 - 02/2000)
5.	Engert, A: 7 articles (05/2004 - 01/2000)
6.	Vallera, Daniel A: 6 articles (05/2006 - 03/2002)
7.	Pastan, I: 6 articles (12/2001 - 04/2000)
8.	Barth, Stefan: 5 articles (09/2008 - 10/2003)
9.	Zhang, Lin: 5 articles (05/2008 - 04/2005)
10.	Onda, Masanori: 5 articles (12/2006 - 06/2002)

Related Diseases

1.	Neoplasms (Cancer) 09/01/2009 - "Inhibition of tumor growth by targeted toxins in mice is dramatically improved by saponinum album in a synergistic way." 01/01/2002 - "Generally, immunotoxins are specifically potent against cancer cells in vitro and in animal models of human malignancies. " 06/15/1994 - "Anti-Tac(Fab)-PE40, a recombinant double-chain immunotoxin which kills interleukin-2-receptor-bearing cells and induces complete remission in an in vivo tumor model." 12/15/1990 - "Immunotoxins are potent cell-killing agents that may be useful in the treatment of cancer. " 09/01/2008 - "Continuous efforts are being made (i) to investigate molecules exclusively expressed on cancer cells, (ii) to improve the specificity and efficacy of these immunotoxins, (iii) to eliminate side effects (iv) to decrease immunogenicity and (v) to improve pharmacokinetics and ensure better drug delivery." Order ALL the reference details at left...
2.	Leukemia 09/01/1996 - "Combined immunochemotherapy regimens using the investigational biotherapeutic agent B43(anti-CD19)-poke-weed antiviral protein (PAP) immunotoxin may offer an effective treatment for refractory B-cell precursor leukemias. " 12/01/1995 - "In this study, we examined the antileukemic efficacy of the B43 (anti-CD19)-pokeweed antiviral protein (B43-PAP) immunotoxin against radiation-resistant BCP leukemia cells. " 04/01/2002 - "Improved cytotoxic activity toward cell lines and fresh leukemia cells of a mutant anti-CD22 immunotoxin obtained by antibody phage display." 05/01/1984 - "Thy 1.2+ leukemia cells eradicated from in vitro leukemia-bone marrow cell mixtures by antibody-toxin conjugates." 01/01/1992 - "Clinical trials using PAP immunotoxins for the treatment of leukemia have been particularly encouraging." Order ALL the reference details at left...
3.	Lymphoma (Lymphomas) 03/01/1985 - "The immunotoxin was not very toxic to pluripotent stem cells; less than 50% of the stem cells were lost under conditions where 5.6 logs of clonogenic lymphoma cells were eliminated from a 100-fold excess of normal marrow cells. " 10/15/1997 - "The patient successfully underwent immunotoxin therapy for lymphoma and has been in remission for 36 months. " 02/01/1991 - "Immunotoxin treatment of leukaemias and lymphomas is also showing promise with clinical responses being observed. " 10/01/1992 - "Several studies treating patients with refractory lymphoma with immunotoxins reported encouraging results but significant production of anti-mouse or anti-toxin antibody. " 12/01/2009 - "The ATG-saporin-S6 immunotoxin showed a strong cytotoxic effect on five lymphoma- and leukaemia-derived cell lines as well as on activated lymphocytes while sparing non-haematological cell lines. " Order ALL the reference details at left...
4.	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) 05/01/2000 - "Immunotoxins against CD19 and CD22 are effective in killing precursor-B acute lymphoblastic leukemia cells in vitro." 12/15/1998 - "Host-mediated antibody-dependent cellular cytotoxicity contributes to the in vivo therapeutic efficacy of an anti-CD7-saporin immunotoxin in a severe combined immunodeficient mouse model of human T-cell acute lymphoblastic leukemia." 01/01/1994 - "Immunotoxin studies in a model of human T-cell acute lymphoblastic leukemia developed in severe combined immune-deficient mice." 02/01/1998 - "B43(anti-CD19)-PAP immunotoxin is a potent inhibitor of protein synthesis in CD19+ B-lineage acute lymphoblastic leukemia (ALL) cells and causes apoptosis. " 06/01/1995 - "An anti-CD72 immunotoxin against therapy-refractory B-lineage acute lymphoblastic leukemia." Order ALL the reference details at left...
5.	Residual Neoplasm 06/01/1982 - "The residual tumor cells were then eliminated by intravenous administration of an anti-delta immunotoxin. " 10/01/1995 - "Ongoing studies are examining the role of targeted toxins in combination with chemoradiotherapy and in minimal residual disease settings." 06/02/1993 - "IMPLICATIONS: The ideal setting for testing the efficacy of intracavitary immunotoxin combined with rHuIFN-alpha after front-line chemotherapy is in patients with residual tumor refractory to additional chemotherapy or in those with toxic effects that prevent delivery of effective doses." 04/01/1993 - "Immunotoxin therapy appears to offer promise in treating the minimal residual disease that remains after induction chemotherapy. " 01/01/1990 - "The administration of immunotoxins (a drug or a cell poison chemically linked to a leukemia-related monoclonal antibody) has been associated with promising results in eradicating minimal residual disease in animal model systems. " Order ALL the reference details at left...

Related Drugs and Biologics

1.	Ricin
2.	Antigens
3.	Antibodies
4.	Exotoxins
5.	Immunotoxins (Immunotoxin)
6.	Immunoconjugates (Immunoconjugate)
7.	Transferrin (beta 2 Transferrin)
8.	Transferrin Receptors (Transferrin Receptor)
9.	Cyclophosphamide (Cytoxan)
10.	saporin

Related Therapies and Procedures

1.	Drug Therapy (Chemotherapy)
2.	Heterologous Transplantation (Xenotransplantation)
3.	Bone Marrow Transplantation (Transplantation, Bone Marrow)
4.	Transplants (Transplant)
5.	Immunotherapy

Best Treatments:
Research Summary Report
on Neoplasms

CureHunter Patient-Physician Summary Reports collect in one document all the medications ever reported in the US National Library of Medicine—1949 to the present—to be effective against your target disease. CureHunter research summary reports will vary in length from 25 to 250 pages. Analytic charts allow you and your physicians to see at a glance your medication options—including new, promising, off-label and experimental all rated for clinical efficacy.

Free Updates for 1 Year
All 20112 Outcomes
Top 200 Key Drugs and Biologics
Top 50 Key Therapies and Procedures
Detailed History Charts
Full Research Reference Details
Sample PDF Report on Psoriasis >>

Price:

$24.00 & Delivery via PDF download
updates for 1 year

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License Details >>

Price:

$490.00 access via web interface
1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m"
1 year subscription

Proceed to Checkout >>